MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

ACADIA Pharmaceuticals Inc

Fermé

SecteurSoins de santé

16.1 -3.19

Résumé

Variation du prix de l'action

24h

Actuel

Min

16

Max

16.61

Chiffres clés

By Trading Economics

Revenu

111M

144M

Ventes

9.2M

260M

P/E

Moyenne du Secteur

12.213

63.778

BPA

0.86

Marge bénéficiaire

55.37

Employés

653

EBITDA

-19M

12M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+57.28% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-254M

2.9B

Ouverture précédente

19.29

Clôture précédente

16.1

Sentiment de l'Actualité

By Acuity

33%

67%

106 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

ACADIA Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 avr. 2025, 23:04 UTC

Actualités

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 avr. 2025, 22:40 UTC

Principaux Mouvements du Marché

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 avr. 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 avr. 2025, 18:51 UTC

Acquisitions, Fusions, Rachats

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 avr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 avr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 avr. 2025, 22:22 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 22:21 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 21:43 UTC

Actualités
Résultats

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 avr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 avr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 avr. 2025, 20:34 UTC

Actualités

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 avr. 2025, 20:23 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 20:15 UTC

Acquisitions, Fusions, Rachats

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 avr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 avr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 avr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 avr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 avr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 avr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 avr. 2025, 18:38 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 18:30 UTC

Actualités

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 avr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 avr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 avr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 avr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparaison

Variation de prix

ACADIA Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

57.28% hausse

Prévisions sur 12 Mois

Moyen 26.14 USD  57.28%

Haut 37 USD

Bas 18 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

15 ratings

9

Achat

6

Maintien

0

Vente

Score Technique

By Trading Central

16.28 / 17.1Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

106 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.